|
|
|
|
Interferon beta is an effective treatment for relapsing multiple sclerosis (MS).As with other protein drugs,neutralizing antibodies(NAB)can develop that reduce the effectiveness of treatment.NAB directed against IFN-B have in vivo biological consequences in patients with MS.The frequency with which MS patients develop NAB against IFN-B is significantly greater with IFN-B-1b therapy compared with IFN-B-1a therapy.Treatment decisions in MS patients treated with IFN-B should take into account development of NAB. |
|